Abstract
Background Exome sequencing has been proposed as the first-tier genetic testing in autism spectrum disorder (ASD). Here, we performed exome sequencing in autistic individuals with average to high intellectual abilities (N = 207) to identify a molecular diagnosis of ASD and genetic modulators of intervention outcomes following social skills group training (SSGT) or standard care.
Methods Within a randomized controlled trial of SSGT, we performed exome sequencing to prioritize variants of clinical significance (VCSs), variants of uncertain significance (VUSs) and generated a pilot scheme to calculate genetic scores representing the genetic load of rare and common variants in the synaptic transmission pathway (GSSyTr and GSSyTc). The association with the primary outcomes (parent-reported autistic traits, Social Responsiveness Scale) was computed using a mixed linear model. Behavioral and genetic features were combined in a machine learning (ML) model to predict the individual response within the cohort.
Results In total, 4.4% (n = 9) and 11.3% (n = 23) of the cohort carried VCSs and VUSs, respectively. Compared to non-carriers, individuals with VCS or VUS together tended to have limited improvements of the interventions (β = 9.22; CI (−0.25, 18.70); P = 0.057) and improved significantly less from standard care (β = 9.35; CI (0.70, 18.00); P = 0.036), but not from SSGT (β = -2.50; CI (−13.34, 8.35); P = 0.65). In addition, both GSSyTr and GSSyTc were associated with differential outcomes in standard care and SSGT groups. Our ML model showed the importance of rare variants for outcome prediction.
Conclusions Autistic individuals with likely pathogenic rare variants identified by exome sequencing might benefit less from the standard care. SSGT could therefore be of heightened importance for this subgroup. Further studies are needed to understand genetic predisposition to intervention outcomes.
Trial registration Social Skills Group Training (“KONTAKT”) for Children and Adolescent With High-functioning Autism Spectrum Disorders (KONTAKT-RCT), NCT01854346. Submitted 20 April 2013 - Retrospectively registered, https://clinicaltrials.gov/ct2/show/record/NCT01854346?view=record
Competing Interest Statement
Sven Bolte is an author of the German and Swedish KONTAKT manuals and receives royalties from Hogrefe publishers. Dr. Bolte discloses that he has in the last 3 years acted as an author, consultant or lecturer for Medice and Roche. Nora Choque Olsson and Ulf Jonsson are authors of the Swedish KONTAKT manuals. Martin Becker is a full-time employee of Bayer AG, Germany. The other authors do not report financial interests or potential conflicts of interest.
Clinical Trial
NCT01854346
Funding Statement
This work was supported by grants from the Swedish Research Council clinical therapy framework grant (921-2014-6999, Drs. Bolte, Tammimies), the Swedish Research Council, in partnership with the Swedish Research Council for Health, Working Life and Welfare, Formas and VINNOVA (cross-disciplinary research program concerning children's and young people's mental health, 259-2012-24, Dr. Bolte), Stockholm County Council (20130314 Dr. Bolte, 20170415 Dr. Tammimies), Swedish Foundation for Strategic Research (ICA14-0028, FFL18-0104, Dr. Tammimies), The Swedish Brain Foundation (Dr. Tammimies), the Harald and Greta Jeanssons Foundations (Dr. Tammimies), Ake Wiberg Foundation (Dr. Tammimies), StratNeuro (Dr. Tammimies), the L'Oreal-UNESCO for Women in Science prize in Sweden with support from the Young Academy of Sweden (Dr. Tammimies), Sallskapet Barnavard (Dr. Tammimies, Ms Li), China Scholarship Council (Ms Li), Drottning Silvias Jubileumsfond (Ms Li) and Committee of Research at Karolinska Institutet (Dr Tammimies).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Written informed consent was obtained from parents or legal guardians, and verbal consent from all participants. All the protocols and methods were followed in accordance with the Declaration of Helsinki and were approved by the ethical review board in Stockholm (Dnr 2012/385-31/4) and the clinical authorities of the two involved counties.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All public data from databases and studies were described in the manuscript. The genetic data is accessible through the Swedish National Data Service (https://snd.gu.se/en) after necessary clearances.
List of abbreviations
- ASD
- autism spectrum disorder
- CNV
- copy number variation
- NDD
- neurodevelopmental disorder
- PRS
- polygenic risk score
- ML
- machine learning
- SSGT
- social skills group training
- ADHD
- attention deficit hyperactivity disorder
- SRS
- Social Responsiveness Scale
- VCS
- variant of clinical significance
- VUS
- variant of uncertain significance
- GSSyT
- genetic score for synaptic transmission
- GSSyTc
- genetic score for synaptic transmission for common variant
- GSSyTr
- genetic score for synaptic transmission for rare variant
- SVM
- support vector machine
- AUC
- area under the receiver operating characteristic curve
